Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annette E Fleckenstein

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2009
Mechanisms underlying methamphetamine-induced dopamine transporter complex formationGregory C Hadlock, Anthony J Baucum, Jill L King, et al.
Frontiers in Psychiatry|April 8, 2026
Trail Making Test performance in early abstinence from methamphetamine: human evidence for a drug-associated Parkinsonian-like phenotypeAlexandru Mihai Dumitrescu, M Frances Vest, Annette E Fleckenstein, et al.
Synapse (New York, N.Y.)|January 23, 2016
An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicityAshley N Fricks-Gleason, Christopher L German, Amanda J Hoonakker, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 12, 2006
Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptakeKristi S Rau, Elisabeth Birdsall, Trent J Volz, et al.
Synapse (New York, N.Y.)|March 4, 2011
Ephedrine decreases vesicular monoamine transporter-2 functionJonathan D Ellis, Christopher L German, Elisabeth Birdsall, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
A single methamphetamine administration rapidly decreases vesicular dopamine uptakeJeffrey M Brown, Evan L Riddle, Verónica Sandoval, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 23, 2015
Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic DeficitsPaula L Vieira-Brock, Lisa M McFadden, Shannon M Nielsen, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 29, 2011
Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposureLisa M McFadden, Greg C Hadlock, Scott C Allen, et al.
Synapse (New York, N.Y.)|December 31, 2010
Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administrationLisa M McFadden, Amanda J Hoonakker, Paula L Vieira-Brock, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 4, 2011
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuseGregory C Hadlock, Katy M Webb, Lisa M McFadden, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
The Journal of Pharmacology and Experimental Therapeutics|January 15, 2009
Mechanisms underlying methamphetamine-induced dopamine transporter complex formationGregory C Hadlock, Anthony J Baucum, Jill L King, et al.
Frontiers in Psychiatry|April 8, 2026
Trail Making Test performance in early abstinence from methamphetamine: human evidence for a drug-associated Parkinsonian-like phenotypeAlexandru Mihai Dumitrescu, M Frances Vest, Annette E Fleckenstein, et al.
Synapse (New York, N.Y.)|January 23, 2016
An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicityAshley N Fricks-Gleason, Christopher L German, Amanda J Hoonakker, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 12, 2006
Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptakeKristi S Rau, Elisabeth Birdsall, Trent J Volz, et al.
Synapse (New York, N.Y.)|March 4, 2011
Ephedrine decreases vesicular monoamine transporter-2 functionJonathan D Ellis, Christopher L German, Elisabeth Birdsall, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
A single methamphetamine administration rapidly decreases vesicular dopamine uptakeJeffrey M Brown, Evan L Riddle, Verónica Sandoval, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 23, 2015
Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic DeficitsPaula L Vieira-Brock, Lisa M McFadden, Shannon M Nielsen, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 29, 2011
Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposureLisa M McFadden, Greg C Hadlock, Scott C Allen, et al.
Synapse (New York, N.Y.)|December 31, 2010
Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administrationLisa M McFadden, Amanda J Hoonakker, Paula L Vieira-Brock, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 4, 2011
4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuseGregory C Hadlock, Katy M Webb, Lisa M McFadden, et al.
Pageof 8